“`html
On November 7, 2025, JP Morgan Cazenove reiterated its coverage of GSK plc – Depositary Receipt (NYSE:GSK) with an Underweight recommendation. The average one-year price target is $44.99/share, suggesting a potential 3.51% downside from the latest closing price of $46.63/share.
The projected annual revenue for GSK is $31,763 million, marking a decrease of 1.25%. Investor sentiment is mixed, with 1,052 funds reporting positions in GSK, reflecting a slight increase of 0.86% in ownership. Institutional ownership of shares rose by 3.04% to 487,489K shares.
Notable investors include Dodge & Cox, which holds 78,758K shares, and Fisher Asset Management, which increased its holdings to 31,338K shares. Primecap Management and Vanguard PRIMECAP Fund also showed increases in their portfolios, with holdings of 27,727K and 19,891K shares, respectively.
“`
